Apollomics, Inc. (NASDAQ:APLMW) Short Interest Update

Apollomics, Inc. (NASDAQ:APLMW) was the recipient of a large decline in short interest in December. As of December 15th, there was short interest totalling 68,200 shares, a decline of 55.0% from the November 30th total of 151,500 shares. Based on an average trading volume of 79,400 shares, the short-interest ratio is presently 0.9 days.

Apollomics Stock Up 8.4 %

NASDAQ APLMW traded up $0.00 on Friday, hitting $0.01. 6,898 shares of the company’s stock were exchanged, compared to its average volume of 52,916. The stock has a 50-day moving average of $0.01 and a 200-day moving average of $0.01. Apollomics has a 52 week low of $0.01 and a 52 week high of $0.04.

About Apollomics

Apollomics, Inc, a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.